The XRCC1 protein, a limiting factor in the BER pathway, is considered to play key roles in DNA damage repair, and the association of XRCC1 genetic polymorphisms with sensitivity to platinum-based chemotherapy treatment has attracted much interest and became a research hotpot in individual treatment for lung cancer patients. This evidence concerns the gene XRCC1 and lung cancer.